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Abstract Recently, several checklists systematically
assessed factors that affect the transferability of cost-
effectiveness (CE) studies between jurisdictions. The role
of the threshold value for a QALY has been given little
consideration in these checklists, even though the impor-
tance of a factor as a cause of between country differences
in CE depends on this threshold. In this paper, we study the
impact of the willingness-to-pay (WTP) per QALY on the
importance of transferability factors in the case of smoking
cessation support (SCS). We investigated, for several val-
ues of the WTP, how differences between six countries
affect the incremental net monetary benefit (INMB) of
SCS. The investigated factors were demography, smoking
prevalence, mortality, epidemiology and costs of smoking-
related diseases, resource use and unit costs of SCS, utility
weights and discount rates. We found that when the WTP
decreased, factors that mainly affect health outcomes
became less important and factors that mainly effect costs
became more important. With a WTP below €1,000, the
factors most responsible for between country differences in
INMB were resource use and unit costs of SCS and the
costs of smoking-related diseases. Utility values had little
impact. At a threshold above €10,000, between country
differences were primarily due to different discount rates,
utility weights and epidemiology of smoking-related dis-
eases. Costs of smoking-related diseases had little impact.
At all thresholds, demography had little impact. We con-
cluded that, when judging the transferability of a CE study,
we should consider the between country differences in
WTP threshold values.
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Introduction
Transferability has been defined as the degree to which the
results of a cost-effectiveness study performed in one
jurisdiction are representative for another jurisdiction,
frequently another country. The term is also used to express
the amount of adaptation that is necessary to make the
results applicable to another jurisdiction [1]. A study that
requires just a few simple adaptations, like a change in unit
costs or discount rate, is more easily transferable than a
study that requires many complicated adaptations, like a
change in resource use pattern or a change in the case mix
of the study population.
The question arises to what extent we can assess trans-
ferability. Recently, several checklists have been developed
which systematically check the transferability of CE studies
between jurisdictions [2–4]. Such checklists contain a list of
issues which must be satisfied before a study is considered
transferable. Examples of such issues are whether the per-
spective and comparators are relevant for the country of
interest, whether the disease epidemiology is comparable in
the country of interest and whether discount rates were
specified. Some of the checklists generate a summary
transferability score, assigning either equal importance to
each issue [2] or weighting the importance of each issue [3].
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The advantage of such checklists is that they force the
user to systematically think about transferability. The dis-
advantage is that the transferability scores are difficult to
interpret. What does a particular transferability score really
say? Moreover, in all of these checklists, there is one aspect
that has been given little consideration, namely the
threshold value for a QALY. Although some checklists
encourage the user to discuss the generalizability of the
results in the light of country-specific decision criteria, the
checklists ignore the fact that the importance of a trans-
ferability issue depends on the threshold value for a QALY.
Issues that are important contributors to between country
differences in CE at a low threshold need not be of equal
importance at a higher threshold. For example, a difference
in the incidence of an infectious disease between two
countries, which causes the incremental cost-effectiveness
ratio (ICER) of a vaccination program to double from
€12,000 in country A to €24,000 in country B, is less
important when the threshold value is €50,000 per QALY
but highly important when the threshold value is €20,000.
As we will discuss later in this paper, no country has an
explicit threshold value for a QALY. However, this does
not mean that there is no threshold. Since no country has
infinite resources available for health care, decisions have
to be made which interventions to reimburse and which
not. At the same time, although heavily criticized, the
QALY is widely regarded as a relevant outcome for deci-
sion-makers. Assuming both the existence of a country-
specific threshold and the acceptance of QALYs as an
outcome measures that is relevant to the decision-makers in
our countries of interest, country-specific INMBs can be
calculated for all relevant countries.
The aim of this paper is to assess whether the extent to
which between country differences influence the country-
specific INMB depends on the threshold value for a QALY.
We ranked several possible causes (in this paper ‘‘transfer-
ability factors’’ or ‘‘factors’’) of between country differences
in CE of smoking cessation support, according to their
impact on the INMB. By doing this for different levels of the
threshold value for a QALY, we studied how the importance
of a transferability factor depends on this threshold value. In
an earlier study, we found that at a threshold value of
€20,000, discount rates and the epidemiology of smoking-
related diseases were important drivers of between country
differences in INMB of smoking cessation interventions [5].
Methods
The BENESCO model
The economic evaluation of smoking cessation support was
based on the Benefits of Smoking Cessation on Outcomes
(BENESCO) model, using a lifetime horizon and a
healthcare sector’s perspective [6]. The BENESCO model
simulates the benefits of quitting smoking in terms of
smoking-related morbidity, mortality and associated med-
ical costs. Diseases included in the model are chronic
obstructive pulmonary disorder (COPD), lung cancer,
chronic heart disease (CHD) and stroke. The model is
structured as a Markov model and follows a hypothetical
cohort of current smokers making a single attempt to quit
smoking at the beginning of the simulation. More infor-
mation on the model can be found in the online appendix
and several publications [7–9].
Smoking cessation support
If a person decides to quit smoking, (s)he can do this
unaided, or using one of the available forms of smoking
cessation strategies. In this paper, we compare three forms
of pharmacological smoking cessation support: nicotine
replacement therapy (NRT), bupropion and varenicline.
NRT is the generic term for any form of smoking cessation
aid which delivers a measured dose of nicotine to the
person using it. Examples include the nicotine patch or
nicotine gum. Bupropion is an antidepressant used to
support smoking cessation [10]. Varenicline is designed to
relieve symptoms of nicotine withdrawal including ciga-
rette craving and block the reinforcing effects of continued
nicotine use [11]. The reference case to which the results of
other countries in this analysis are compared is an eco-
nomic evaluation performed from the Dutch health care
perspective. In this study, NRT has been shown to be cost-
effective compared to unaided cessation, bupropion was
dominant over NRT and varenicline was dominant over
bupropion [7].
Cost-benefit
The primary outcome of the economic evaluation was the
INMB. The INMB was chosen because it explicitly
incorporates the threshold value for the willingness-to-pay
(WTP), or the societal value for a QALY (k). Hence, we
could study the extent to which the importance of the
transferability factors depends on the k (see paragraph
below). The INMB was calculated for different values of
k ranging from 0 to €50,000. Comparing two smoking
cessation interventions, A and B, the INMB was calcu-
lated as:
QALY Að Þ  QALY Bð Þ½   k  Costs Að Þ  Costs Bð Þ½ :
A positive INMB indicates that the net benefits of inter-
vention A are higher than the net benefits of intervention B.
A negative INMB indicates that the net benefits of inter-
vention A are lower than the net benefits of intervention B.
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Factors affecting transferability
Within the BENESCO model, all variables except the
risk ratio of getting a smoking-related illness were
changed to calculate country-specific cost-effectiveness.
These variables can intuitively be grouped in a total of
nine transferability factors, which could potentially cause
differences in the cost-benefit of smoking cessation
support between countries. We investigated each of these
factors. Each transferability factor consisted of a group
of country-specific input parameters which were varied
simultaneously. Demography included the total number
of people older than 18 years of age in six age/gender
classes. Smoking prevalence refers to the percentage of
smokers, non-smokers and former smokers in each age/
gender class. All-cause mortality was the percentage of
the total number of people in each age/gender class that
dies during a single year. The epidemiology of smoking-
related diseases consisted of three elements: the inci-
dence rates, prevalence rates and annual cause-specific
mortality rates by age/gender class. The costs of smok-
ing-related diseases were separated into first year costs
and costs in subsequent years, except for COPD. The
amount of resource use (i.e., medication and counselling)
associated with the SCS and the unit costs of these
resources were the two elements defining the intervention
costs. The utility weights were defined both for the
general population and for patients with a smoking-
related disease. The discount rates for both costs and
outcomes were set equal to the values recommended in
2007 in the national guidelines for economic evaluations.
For each country, we adopted a health care perspective.
Information on the main input factors can be found in
the ‘‘Appendix’’.
The importance of each transferability factor
Based on the hierarchy of effectiveness of the smoking
cessation interventions, we calculated the INMB of NRT
versus unaided cessation, bupropion versus NRT and
varenicline versus bupropion in the Netherlands [7].
These results were used as the reference values. We then
changed the Dutch input values of each of the nine factors
individually to the country-specific values for Germany,
Sweden, the UK, Belgium and France [5, 8, 12, 13]. This
changes the INMB. The percentage of change in the
INMB was then averaged over the three treatment com-
parisons. Each factor is then rank ordered from highest
(1) to lowest (9) percentage of change in INMB. We
compare these rankings for different threshold values,
ranging from €0 to €50,000 per QALY, for each country
separately.
Results
The INMB of NRT versus unaided cessation in the Neth-
erlands at a WTP threshold of €20,000 per QALY was
€1.42 million. The INMB of bupropion versus NRT was
€0.39 million, and the INMB of varenicline versus
bupropion was €0.90 million. Table 1 shows the ranking of
factors at different threshold values for a QALY, after
replacing the Dutch reference values with the German
country-specific values. It is clear from this table that the
threshold value has a considerable impact on the impor-
tance of each factor.
This can be seen most clearly for the cost of smoking-
related diseases, resource use, unit costs and utility
weights. The INMB is calculated as the difference in
QALYs multiplied by k minus the difference in costs.
Hence, the QALY gains are weighted with the k before
subtracting the additional costs. When k decreases, the
transferability factors that mainly affect the health out-
comes are given less weight and become less important,
whereas the transferability factors which mainly affect the
costs become more important. Among the latter are the
costs of smoking cessation support, which are driven by
the resources used and the unit costs of these resources, and
the costs of smoking-related diseases. When k increases,
the transferability factors with a large impact on the
QALYs are given a higher weigh, increasing their impor-
tance as a cause of between country differences in net
benefit. As a consequence, utility weights, epidemiology
(mainly incidence and mortality) of smoking-related dis-
eases and smoking prevalence become more important.
When replacing Dutch by German input values, the
discount rate, which changed from 4% for costs and 1.5%
for effects in the Netherlands to 5% for both costs and
effects in Germany, led to the highest percentage of change
in INMB at thresholds of €5,000 or higher. At lower
thresholds, the relative importance of the discount rate
decreases, with the resource use taking over as the most
important factor. All-cause mortality and demography are
relatively unimportant at all threshold values.
Similar tables result for the other countries. They are
shown in the ‘‘Appendix’’. For the other four countries, the
same general overview can be seen, although there are
individual differences. Tables on the outcomes of other
countries can be found in the ‘‘Appendix’’. In all countries,
unit costs and/or resource use are amongst the two most
important causes of between country differences in cost-
benefit at low thresholds. At high thresholds, utility
weights, discount rates and the epidemiology of smoking-
related diseases are the three most important factors for all
countries, except for Belgium which had almost the same
discount rates as in the Netherlands.
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Figure 1 shows the percentage of change in the INMB
of NRT versus unaided cessation, when substituting the
reference case input values to the German values, at vari-
ous levels of k. The results were comparable for the other
pair-wise comparisons of smoking cessation interventions
(not shown, available on request). At a k of €0, substituting
Dutch resource use by German resource use led to the
greatest change in INMB, a decrease of 92%. The second
most important transferability factor was the costs of
smoking-related diseases, decreasing the INMB with 29%.
At a k of €500, Germany-specific resource use still caused
the INMB to change most, but now followed by the dis-
count rates. At a k of €5,000 or above, the discount rates
had the highest impact on the INMB, causing a decrease in
INMB of 99%, followed by the utility weights, causing a
decrease in INMB of 25%.
The closer the threshold value of a QALY was to the
original ICER in the reference country—in this case €1,637
per QALY—the more the INMB was affected by a change to
country-specific input data. This was true for every trans-
ferability factor, since the INMB of the base case comparison
is close to zero with a k close to the ICER. For most trans-
ferability factors, the sign of the impact on the INMB at a
threshold of €1,000 or lower switched from positive to
negative or vise versa at a threshold of €5,000 or higher. Only
the factor discount rates for Sweden and the UK and the
factor epidemiology for Belgium and Sweden show a
slightly different pattern. The reason is that the INMB of the
base case comparison is always positive with a k above the
value of the ICER, but negative with a k below the ICER. A
similar change in INMB due to a new country-specific var-
iable value will therefore have a directly opposite effect.
Figure 2 shows, for various levels of k, the change in
INMB of NRT versus unaided cessation, when all refer-
ence case input values are simultaneously replaced by
country-specific values. This change to the country-specific
INMB is shown for each country separately. At lower
levels of k, the INMB changes most when adapting the
Dutch input data to the UK input data. This is because the
resource use and costs of NRT in the UK differ most from
that in the Netherlands, i.e., NRT is considerably less
expensive in the UK than in the Netherlands. At higher
levels of k, the INMB changes most when adapting the
Dutch input data to the German input data. This is because
of the great difference in discount rates.
Discussion
This paper has clearly shown that, when we transfer a foreign
economic evaluation to the country of interest, the factor
which should most carefully be adapted is driven by the
threshold value for a QALY. We feel that this aspect has been
given too little attention in the transferability debate until
now. When discussing the transferability of smoking ces-
sation evaluations in countries with low threshold values, we
should pay most attention to the country-adaptation of the
cost drivers, i.e., the costs of the interventions and the disease
that are studied. In countries with high threshold values, we
should pay most attention to the country-adaptation of the
factors that affect the health outcomes. These include disease
epidemiology and utility values. Although the results are
specific for smoking cessation interventions, and indeed for
the BENESCO model, we feel this conclusion is applicable
to similar interventions of a preventative nature that require
initial investments which by far precede the returns on these
investments in terms of improved health outcomes and
savings in the costs of health care utilization. In addition, we
feel that based on this paper, the threshold value for a QALY
should be an integral part of the investigation of transfer-
ability for all economic evaluations.
The approach taken in this paper assumes the acceptance
of the QALY as a relevant decision-making outcome and
the existence of threshold values, either explicit or implicit.
Table 1 Univariate ranking of factors after changing to the German values, at different threshold values for the willingness-to-pay (WTP) for a
QALY
Threshold value
for WTP
Demography All-cause
mortality
Smoking
prevalence
Epidemiology Costs of smoking-
related diseases
Resource
use
Unit
costs
Utility
weights
Discount
rates
€0 7 8 6 5 3 1 2 9 4
€100 7 8 6 5 4 1 2 9 3
€500 8 9 6 5 4 1 3 7 2
€1,000 8 9 7 5 3 1 4 6 2
€5,000 8 9 7 4 6 2 5 3 1
€10,000 8 9 6 3 7 4 5 2 1
€20,000 8 9 4 3 7 5 6 2 1
€50,000 7 9 4 3 8 5 6 2 1
Ranked according to the percentage change in INMB compared to the reference country, averaged over three pair-wise comparisons of smoking
cessation strategies
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The reason that the role of the threshold value has been
largely ignored in the transferability discussion may be
related to the fact that we are far from reaching a consensus
on the maximum willingness to pay for a QALY. There is
not a single jurisdiction where the threshold value is really
fixed. With respect to the countries in our current study,
NICE (National Institute for Health and Clinical Excel-
lence) in the UK mentions the most explicit threshold
value, but they too reject the use of a single, absolute
threshold, instead preferring to make decisions on a case-
by-case basis. NICE is unlikely to reject a technology with
a ratio in the range of £5,000 – £15,000 per QALY solely
on the grounds of cost ineffectiveness but would need
special reasons for accepting technologies with ratios over
£25,000 – £35,000 per QALY as cost effective [14]. In the
Netherlands, a threshold of €20,000 per QALY is often
cited. However, this threshold was obtained from economic
evaluations of preventive interventions and is certainly not
used consistently [15]. Currently, there is discussion in the
Netherlands on increasing the threshold value depending
on the burden of the disease of interest, with a maximum
threshold of up to €80,000 for very severe diseases [16,
17]. In Germany, the IQWiG (Institut fu¨r Qualita¨t und
Wirtschaftlichkeit im Gesundheitswesen) has prepared
guidelines for economic evaluation as part of the evalua-
tion of the value of pharmaceuticals [18], but coverage
does not depend on any externally set maximum standard.
In 2008, the Belgian KCE (Federal Knowledge Centre for
Health Care) started to produce methodological reports in
order to help standardize the methodology used for health
technology assessment [19]. One such report mentions that
CE is now only rarely used as an argument for reim-
bursement. The budget impact is considered more impor-
tant. This report was intended as a starting point for a
discussion on the role of threshold values in Belgium [20].
In Sweden, no guidance has been given as to acceptable
cost-effectiveness ratios, defined in terms of cost per
QALY or otherwise, although cost-effectiveness is
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Fig. 1 Percentage of change
in the INMB of NRT versus
unaided cessation, when
replacing Dutch input values for
each factor by the German input
values, at different threshold
values for the willingness-to-
pay (WTP) for a QALY.
F1: demography, F2: smoking
prevalence, F3: mortality,
F4: epidemiology, F5: costs of
smoking-related diseases,
F6: resource use, F7: unit costs,
F8: utility weights, F9: discount
rates
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considered a crucial aspect in the Swedish reimbursement
system [21]. Rather than apply a single threshold, there
may be different (implicit) thresholds depending on the
severity of the disease or an assessment of patient need
[22]. In France, no threshold value is used when making
health care decisions [23].
In a cost-utility analysis, an intervention is found to be
cost-effective if the cost per QALY falls below the WTP
for a QALY. This value is used as an external threshold
value against which the ICER is compared. In the cost-
benefit analysis, the societal value of a QALY is directly
incorporated into the analysis. For an intervention to be
cost-effective, the INMB (calculated as [QALY(A) –
QALY(B)] 9 k – [Costs(A) – Costs(B)]) needs to be
positive. In the net benefit approach, it is apparent that the
impact of a country-specific model parameter on the
decision to adopt an intervention depends on the threshold
value of the QALY. Though not immediately visible in the
cost-utility analysis itself, the impact of a parameter on the
probability that the ICER falls below the threshold value
equally depends on the level of this threshold value.
Whether or not the threshold value is explicitly incorpo-
rated into the analysis does to affect the importance of a
country-specific parameter in the transferability discussion.
The consequence of our findings may be that we have to
adjust the available transferability check lists to encourage
checking whether there might be differences in the will-
ingness to pay between the countries, next to checking how
well a foreign study represents the circumstances in the
country of interest and how much effort is required to adapt
particular data inputs to the country of interest. For
example, NRT, bupropion and varenicline are currently not
covered by the basic health care insurance in the Nether-
lands, although the health insurance board CVZ has
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Fig. 2 Percentage of change
in the INMB of NRT versus
unaided cessation, when
simultaneously replacing Dutch
input values for all
transferability factors by the
country-specific input values
at different threshold values for
the willingness-to-pay (WTP)
for a QALY. Demography,
smoking prevalence, mortality,
epidemiology, costs of
smoking-related diseases,
resource use, unit costs, utility
weights, discount rates
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recently advised the Ministry of Health to reimburse them
as part of an integrated smoking cessation program [24].
This implies a current willingness to pay of €0. Conse-
quently, when future foreign CE studies of new smoking
cessation interventions (e.g., a vaccine) become available,
the transferability of the cost of this intervention to the
Netherlands will be driving the reimbursement discussion.
In contrast, in the UK, where NRT, bupropion and varen-
icline are already paid by the NHS, the discussion on the
transferability of foreign cost-effectiveness studies of such
a drug might focus more on the representativeness of the
epidemiology of smoking-related diseases for the UK and
the utility values of patients having a smoking-related
disease.
Conclusion
When judging the transferability of a CE study from one
jurisdiction to another, it is relevant to consider the
between country differences in threshold values per
QALY. Between country, differences in cost-effectiveness
are determined by between country differences in unit
costs, disease epidemiology, discount rates etc., but the
importance of each of these is influenced by the threshold
value for a QALY. Between country differences that are
important at a low threshold value might be less important
at a high threshold value and vice versa.
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Appendix: Background information BENESCO model
and additional results
The projections of the effects of smoking cessation were
based on the BENESCO (Benefits of Smoking Cessation
on Outcomes) model [7]. The BENESCO model simulates
the consequences of smoking and the benefits of quitting in
terms of smoking-related morbidity, mortality and associ-
ated medical costs in a population. The model is structured
as a Markov model (cycle length 1 year) and follows a
hypothetical cohort of current smokers making a single
attempt to quit smoking at the beginning of the simulation.
The cohort is followed from the time of their quit attempt
until all members of the cohort have died. Individuals are
classified into one of three smoking states, i.e., smoker,
recent quitter (abstinent 1–5 years after successful quit
attempt) or long-term quitter. Transition probabilities
between smoking states in the first year depend on cessa-
tion rates of the interventions, while the probabilities after
1 year depend on relapse rates, which in turn depend on
time since quitting. The model simulates the age, gender
and smoking status-specific incidence and mortality of four
major diseases for which smoking is a well-established risk
factor: chronic obstructive pulmonary disease (COPD),
lung cancer, coronary heart disease and stroke. Smoking
state-specific incidence and mortality rates were calculated
using relative risks [25, 26]. The incidence and mortality
rates for recent quitters were calculated using the relative
risks of former smokers versus never smokers, while the
rates for long-term quitters were assumed to be the same as
those of never smokers. Because COPD and lung cancer
are chronic progressive conditions, these diseases were
given hierarchical prominence over the other conditions
with acute recurrent events. This means that individuals
with COPD or lung cancer remain in this state until they
die and cannot move to a CHD or stroke state, whereas
individuals with CHD or stroke can move to the COPD or
lung cancer state. A patient cannot have two diseases at the
same time. The model calculates the total number of
smokers and quitters that have one of the smoking-related
diseases as well as the number of deaths (due to one of the
smoking-related diseases and overall) over the time hori-
zon of the simulation. Based on these numbers, the total
health care costs associated with the different disease states
and the total number of (quality adjusted) life years are
calculated. The model uses three age bands: 18–34 years,
35–64 years and 65 years and older. Subjects alive in the
model at age 99 years are all assumed to die in the next
cycle. It is assumed that there is no smoking-related mor-
bidity or mortality in the 18–34 years age class.
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